EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications

Fatma Haddad, Ghadeer Dokmak iD, Maryam Bader, Rafik Karaman iD

Life · 14.04.2023 · 13 (4) · 1012

DOI: 10.3390/life13041012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 14.04.2023. Verfasst von Fatma Haddad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 9103401, Palestine. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a complex metabolic condition that can have a negative impact on one’s health and even result in mortality. The management of obesity has been addressed in a number of ways, including lifestyle changes, medication using appetite suppressants and thermogenics, and bariatric surgery for individuals who are severely obese. Liraglutide and semaglutide are two of the five Food and Drug Administration (FDA)-approved anti-obesity drugs that are FDA-approved agents for the treatment of type 2 diabetes mellitus (T2DM) patients. In order to highlight the positive effects of these drugs as anti-obesity treatments, we analyzed the weight loss effects of T2DM agents that have demonstrated weight loss effects in this study by evaluating clinical studies that were published for each agent. Many clinical studies have revealed that some antihyperglycemic medications can help people lose weight, while others either cause weight gain or neutral results. Acarbose has mild weight loss effects and metformin and sodium-dependent glucose cotransporter proteins-2 (SGLT-2) inhibitors have modest weight loss effects; however, some glucagon-like peptide-1 (GLP-1) receptor agonists had the greatest impact on weight loss. Dipeptidyl peptidase 4 (DPP-4) inhibitors showed a neutral or mild weight loss effect. To sum up, some of the GLP-1 agonist drugs show promise as weight-loss treatments.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 agonistT2DMlossobesityweight

Autor:innen und Institutionen

  • Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 9103401, Palestine.
  • Faculty of Life Sciences, University of Bradford, Bradford BD7 1DP, UK.
  • Department of Sciences, University of Basilicata, 85100 Potenza, Italy.

ORCID-Profile: Ghadeer Dokmak, Rafik Karaman

Zitieren

APA

Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023). A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. Life, 13(4), 1012. https://doi.org/10.3390/life13041012

Vancouver

Haddad F, Dokmak G, Bader M, Karaman R. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. Life. 2023;13(4):1012. doi:10.3390/life13041012

BibTeX
@article{Haddad2023,
  author = {Haddad, Fatma and Dokmak, Ghadeer and Bader, Maryam and Karaman, Rafik},
  title = {A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications},
  journal = {Life},
  year = {2023},
  volume = {13},
  number = {4},
  pages = {1012},
  doi = {10.3390/life13041012}
}
Kostenlos starten →